Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
复制标题
DOI：
10.1016/s0140-6736(08)61845-0
复制
发表时间：
2009-01-24
期刊：
影响因子：
168.9
通讯作者：
Montalescot, Gilles
中科院分区：
文献类型：
--
作者：
Collet, Jean-Philippe;Hulot, Jean-Sebastien;Montalescot, Gilles
背景氯吡格雷和小剂量阿司匹林已成为预防急性冠脉综合征或支架置入术后复发的主要口服抗血小板方案。频繁的遗传功能变异681。细胞色素P450 209的G>；A(*2)是氯吡格雷抗血小板作用个体间差异很大的重要因素。方法1996年4月1日至2008年4月1日，259例青年患者接受氯吡格雷治疗，观察其基因多态性对患者长期预后的影响。
Background Clopidogrel and low-dose aspirin have become the mainstay oral antiplatelet regimen to prevent recurrent ischaemic events after acute coronary syndromes or stent placement. The frequent genetic functional variant 681. G>A (*2) of cytochrome P450 209 (CYP2C19) is an important contributor to the wide variability between individuals of the antiplatelet effect of clopidogrel. We assessed whether the CYP2C19*2 polymorphism affected long-term prognosis of patients who were chronically treated with clopidogrel.Methods Between April 1, 1996, and April 1, 2008, 259 young patients (aged